The public biotech markets weren't alone in taking a beating in the first quarter; venture capital investments in private U.S. biopharmas tracked by BioWorld Snapshots also saw a steep decline, with companies raising about $1.6 billion, compared to $1.9 billion in the first quarter of 2015.